282 related articles for article (PubMed ID: 36053302)
41. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.
Nicoletti A; Ponziani FR; Biolato M; Valenza V; Marrone G; Sganga G; Gasbarrini A; Miele L; Grieco A
World J Gastroenterol; 2019 Sep; 25(33):4814-4834. PubMed ID: 31543676
[TBL] [Abstract][Full Text] [Related]
42. The Influence of Gut Dysbiosis in the Pathogenesis and Management of Ischemic Stroke.
Chidambaram SB; Rathipriya AG; Mahalakshmi AM; Sharma S; Hediyal TA; Ray B; Sunanda T; Rungratanawanich W; Kashyap RS; Qoronfleh MW; Essa MM; Song BJ; Monaghan TM
Cells; 2022 Apr; 11(7):. PubMed ID: 35406804
[TBL] [Abstract][Full Text] [Related]
43. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
Xie C; Halegoua-DeMarzio D
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
[TBL] [Abstract][Full Text] [Related]
44. Roles of gut microbes in metabolic-associated fatty liver disease.
Chen CY; Ho HC
Tzu Chi Med J; 2023; 35(4):279-289. PubMed ID: 38035063
[TBL] [Abstract][Full Text] [Related]
45. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
[TBL] [Abstract][Full Text] [Related]
46. Dietary lipids, gut microbiota and lipid metabolism.
Schoeler M; Caesar R
Rev Endocr Metab Disord; 2019 Dec; 20(4):461-472. PubMed ID: 31707624
[TBL] [Abstract][Full Text] [Related]
47. Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.
Tokuhara D
Front Nutr; 2021; 8():700058. PubMed ID: 34250000
[TBL] [Abstract][Full Text] [Related]
48. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
[TBL] [Abstract][Full Text] [Related]
49. Unique microbial-derived volatile organic compounds in portal venous circulation in murine non-alcoholic fatty liver disease.
Reid DT; McDonald B; Khalid T; Vo T; Schenck LP; Surette MG; Beck PL; Reimer RA; Probert CS; Rioux KP; Eksteen B
Biochim Biophys Acta; 2016 Jul; 1862(7):1337-44. PubMed ID: 27085070
[TBL] [Abstract][Full Text] [Related]
50. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
[TBL] [Abstract][Full Text] [Related]
51. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
Bakhshimoghaddam F; Alizadeh M
Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
[TBL] [Abstract][Full Text] [Related]
52. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
Ni Y; Ni L; Zhuge F; Fu Z
Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
[TBL] [Abstract][Full Text] [Related]
53. Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.
Mouzaki M; Bandsma R
Curr Drug Targets; 2015; 16(12):1324-31. PubMed ID: 25882223
[TBL] [Abstract][Full Text] [Related]
54. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
[TBL] [Abstract][Full Text] [Related]
55. Yanning Syrup ameliorates the lipopolysaccharide-induced inflammation: Adjusting the gut microbiota, short-chain fatty acids, and the CD4
Wei D; Ma P; Fan Q; Yu H; Peng Y; Li X
J Ethnopharmacol; 2022 Jan; 283():114729. PubMed ID: 34634365
[TBL] [Abstract][Full Text] [Related]
56. The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease.
Zhang DY; Zhu L; Liu HN; Tseng YJ; Weng SQ; Liu TT; Dong L; Shen XZ
Drug Des Devel Ther; 2019; 13():2249-2270. PubMed ID: 31308634
[No Abstract] [Full Text] [Related]
57. Review article: insights into the bile acid-gut microbiota axis in intestinal failure-associated liver disease-redefining the treatment approach.
Wang Y; Zheng L; Zhou Z; Yao D; Huang Y; Liu B; Duan Y; Li Y
Aliment Pharmacol Ther; 2022 Jan; 55(1):49-63. PubMed ID: 34713470
[TBL] [Abstract][Full Text] [Related]
58. Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice.
Li X; Zhao W; Xiao M; Yu L; Chen Q; Hu X; Zhao Y; Xiong L; Chen X; Wang X; Ba Y; Guo Q; Wu X
J Ethnopharmacol; 2022 Aug; 294():115333. PubMed ID: 35500802
[TBL] [Abstract][Full Text] [Related]
59. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
[TBL] [Abstract][Full Text] [Related]
60.
Li H; Shi J; Zhao L; Guan J; Liu F; Huo G; Li B
J Agric Food Chem; 2021 Jan; 69(1):183-197. PubMed ID: 33353302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
